PFE Articles, Pfizer Inc. - From 03/15/24

Thursday, Immuneering Corporation (NASDAQ:IMRX) revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-...

Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization...

Pfizer Inc. (NYSE: PFE) shares closed slightly higher on Wednesday. The New York-based pharmaceutical giant recently said that the European Commis...

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. (NYSE: PFE) as his final ...

Tuesday, Pfizer Inc (NYSE:PFE) announced that a Phase 3 study of the antibody-drug conjugate Adcetris (brentuximab vedotin) combined with...

Pharmaceutical giant Pfizer Inc (NYSE:PFE) is redirecting its strategic focus from COVID to cancer drugs to bounce back from a tumul...

RBC Capital Markets upgraded REGENXBIO Inc (NASDAQ:RGNX), a company focused on developing gene therapies. Recently, REGENXBIO reported ad...

Retail traders have been observed to be selling off their shares in the ‘Magnificent Seven’ tech stocks, with a noticeable shift toward...

Wednesday, the FDA approved Pfizer Inc’s (NYSE:PFE) inotuzumab ozogamicin (Besponsa) for pediatric patients one year and older...

ViiV Healthcare, majority owned by GSK Plc (NYSE:GSK), with Pfizer Inc (NYSE:PFE) and Shionogi Limited as shareholder...